History

We aim to be a global healthcare leader, going beyond the Korean market

Present 2000 1990 1980 1970 1960 ~

Growth to a global healthcare group

Present ~ 2010

2019: Acquired International Quality Management System Standard ISO9001; Completed phase 3 clinical tests for the next-generation gastroesophageal reflux disease medicine, ‘Fexuprazan’; Received ‘Best 100 Companies to Work at in Korea’ award; Received Minister of Employment and Labor Award at the ‘2019 Company Togetherness Awards & CSR Film Festival’; Government Innovative Pharmaceutical Company award; Launched proprietarily developed botulinum toxin ‘Nuceiva’ (Canadian product name) in Canada; Received sales permit in Europe for proprietarily developed botulinum toxin ‘Nuceiva’ (European product name); Acquired International Environmental Safety and Health Certification 'ISO 14001', 'ISO 45001'; US FDA designated new pulmonary fibrosis drug DWN12088 as rare drug; Founded ‘Don’t Wait Project Volunteer Corps 1’ for the healthy life of people with developmental disorders; URSA 300mg’, acquired indication for ‘prevention of gallstone after stomach incision’ for the first time in the world; Officially launched proprietarily developed botulinum toxin ‘Jeuveau’ (US product name) in the US; Launched ‘Olomax’ which simultaneously targeting high blood pressure and hyperlipidemia; Officially opened ‘Daewoong Pharmaceutical News Room’; ‘Nabota’ phase 3 clinical trial results in US was published in SCI-level international academic journal; Investment cooperation with Vietnam’s largest pharmaceutical company ‘Traphaco’; New pulmonary fibrosis drug DWN12088 selected as government-supported project; Hyangnam plant acquired International Safety Health Management System Standard ISO 45001; Internally developed botulinum toxin approved by USFDA, being the first in Asia
2018: Acquired Anti-Corruption Management System ‘ISO 37001’; Quality Circle received Presidential Gold and Silver Award at the ‘National Quality Management Convention’; Nabota acquired the first eye wrinkle indication among domestic botulinum toxin; Quality Circle received the first Grand Prize at the 2018 International Convention on QC Circles (ICQC2018) in the pharmaceutical industry; Established ‘Health Life/Technology Coexistence Fund’; Nabota plant received EU GMP approval; Nabota plant received Canadian GMP approval; Established ‘Daewoong Infion’ bio research center in Indonesia; New drug DWP14012 selected as government-supported project; Nabota plant received cGMP approval in the US; Chairman Yoon Jae-seung, Vice-chairman Lee Jong Wook resigned; Yoon Jae-Chun, Jeon Sengho appointed as CEO to begin professional management system
2017: 'Daewoong Infion’ selected as the best bio pharmaceutical company award; Completed Nabota Plant 2 with 4.5 million vials production capability annually; Completed construction of the Osong Plant in Chungbuk with high-tech cGMP facilities; Hyangnam plant re-certified as ‘2017 Gyeonggi Good Work Place Company (GGWP)’
2016: Acquired certification for Outstanding Human Resource Development Institute; Daewoong Pharmaceutical Research Center ‘Daewoong Bio Center’ completed; Prime Minister’s Citation for 'Good Gender Equality Employment Company’; Antibiotic 'Daewoong Meropenem Injection' acquired US FDA approval; Received ‘AA’ rating for two consecutive years from the Fair Trade Commission’s '2016 CP ratings'
2015: Began construction of new plant in Osong, Chungbuk with cGMP levels; Honorary Chairman Yoon Young-hwan received ‘Most Respected Entrepreneur of Korea Award’; Established ‘Ggeumteul Ggeumteul Playground’, an obstacle-free playground at Seoul Children’s Park; Began co-operation with Hanol Bio Pharma; Completed the ‘Daewoong Infion’ bio plant in Indonesia; Received Presidential Award on Fair Trade Day; Olostar received ‘Technology Award’ at the 16th Korean New Drug Awards, New Drug Development Sector; Received CP rating of ‘AA’; Inauguration of Lee Jong Wook as vice-chairman
2014: Received Prime Minister’s Award in science technology at the ‘Korean New Growth Management Awards’; ‘Nabota’ selected as world-class product (MOTIE, KOTRA); Selected for the ‘2014 Gyeonggi Good Work Place Company’ (Gyeonggi Small and Medium Business Center, Gyeonggi-do); Established ‘Daewoong Pharmaceutical Liaoning Research Institute’ in China; Established Japanese corporation; Inauguration of Yoon Jae-seung as chairman, and Yoon Young-hwan as honorary chairman; Received AA in corporate credit rating; Selected as ‘work-study program’ company (HRD Korea); Launched botulinum toxin ‘Nabota’ in Korea; Launched new compound Olmesartan-Rosuvastatin drug 'Olostar' in Korea; Received ‘Technology Export Award’ at the Korean Drug Development Awards (Korea Drug Research Association)
2013: Received Prime Minister’s Award for Family-friendly Company; Acquired 2013 Family-friendly Company certification; Received 2013 Innovative Pharmaceutical Company Award; Acquired Chinese pharmaceutical company ‘Baifeng’ to establish Liaoning Daewoong Pharmaceutical; Credit rating predicted to be upgraded to A+Positive; Registered utility model for the ‘Caretropin Pen Injection’ in Russia
2012: Established ‘Daewoong-Infion’ joint-venture in Indonesia; Established corporation in India; ‘Caretropin Pen Injection’ received ‘2011-2012 World Star Award’; Selected for the Global Corporate Fostering Project in 'World Class 300'; Selected as 'Innovative Pharmaceutical Company’
2011: Opened the first in-company childcare facility in pharmaceutical industry ‘Little Bear Day Care Center’; Pen injection received Minister of Knowledge and Economy; URSA and Albis received quality certification (GH); Family-friendly company certification extended to the end of 2013
2010: URSA selected as world-class product; Implemented world’s first herpes labialis treatment with recurrence prevention effects

Daewoong introduced its outstanding R&D capabilities by developing "first-in-class“ and "best-in-class" products

2009 ~ 2000

2009: Next-generation pain killer new drug DWP05195 began clinical trials; Established pharmaceutical research institute in India; Received Prime Minister’s Award at the 'National Productivity Awards’; Established US corporation
2008: Established corporation in Thailand; Acquired outstanding family-friendly company from Ministry of Health, Welfare and Family Affairs; Awarded at National Productivity Awards (leadership, innovation activities sector); Established obstacle-free playground at the National Assembly‘s day care center; Received appreciation plaque from Yongwol-gun office for the Yongwol ‘1 Company 1 Village' program; Received ‘Korean Association on Smoking and Health Chairman’s Appreciation Plaque’ on No Smoking Day; Easyef received the first international common name certified from WHO
2007: Established corporation in the Philippines; Corporate credit rating upgraded to A+; Selected as outstanding labor-management culture company; Selected as outstanding company for productivity improvement at the Productivity and Innovation Awards; Released Korea’s first 100mg high-content CoQ10; Released high-content vitamin B compound ‘Impactamin Power’
2006: Established branch in China; Minister of Health and Welfare award for family-friendly company; Established obstacle-free playground at Seoul Forest; Lee Jong Wook inaugurated as CEO
2005: Established corporation in Indonesia; 'Daewoong Coenzyme Q10' awarded by Minister of Health and Welfare Award at the Health Industry Technology Conference; 'Daewoong Coenzyme Q10' received Jang Young-shil Award; Appreciation plaque during parliamentary inspection by the Health and Welfare Committee
2004: Established Vietnam office; Donation to Beautiful Store (Nonhyeon Store)
2003: Daewoong Pharmaceutical Hyangnam Plant acquired ISO14001; Hyangnam Plant acquired International Safety Health Management System certification OHSAS18001; Completed high-tech automated logistics center / implemented APS system; Successfully developed Coenzyme Q10 for the second time in the world
2002: Grand Prize at the Korea Digital Awards; Received Economic Justice Award; Daewoong and Daewoong Pharmaceutical split up
2001: Easyef received KT (New Technology Certification Mark); Launched world’s first number 1 biotechnology new drug Easyef which is developed in Korea
2000: Hyangnam plant certified as outstanding manufacturing plant (KAIST)

Bold R&D investments and entered of new drug development

1999 ~ 1990

1999: Entered phase 2 for Easyef
1998: Chairman Yoon Young-hwan received Order of Civil Merit, Camellia Medal; Implemented enterprise resource planning (ERP) system
1997: Yoon Jae-seung inaugurated as CEO; Easyef won the Chungmugong Patent Technology Award; Received Minister of Education Award at the Industry-Academic Cooperation Awards
1996: Received Facility Management Award at the National Quality Convention; Received Minister of Education Award at the Industry-Academic Cooperation Awards
1995: Began full operation of the Management Information System
1994: Received Economic Justice Award; Sales exceeded 100 billion KRW; Lee Cheol-bae appointed as honorary chairman
1992: Received Prime Minister’s Award on Labor Day; Completed Hyangnam KGMP plant 2
1991: Prime Minister’s Award at the Industry Promotion Agency Quality Master Awards; Labor Peace Award (Labor and Industriousness Award) from Central Labor Economic Research Institute; Received Outstanding Trademark Award from the Korea Intellectual Property Office; Received Presidential Award by the Ministry of Labor on Labor Day; Received Appreciation Plaque at the 37th General Conference of the Korean Pharmaceutical Association; The first exports, in pharmaceutical industry, to the Soviet Union
1990: Received Korea International Trade Association Chairman Award for increased exports; Received presidential award for the 5 million USD export tower; Received silver medal (indirect sector) Prime Minister’s Award at the National Quality Management Circle Convention

Built foundation for technological partnerships and ventures with foreign companies

1989 ~ 1980

1989: Received gold medal (direct sector) Prime Minister’s Award at the National Quality Management Circle Convention; Received gold medal at the National Quality Management Convention; Developed Pharmaceutical Medical Journal Management Program (PMS)
1988: Moved HQ to Samseong-dong
1987: Received Order of Iron Tower Industry for labor-management sector; Received Order of Iron Tower Industry for science technology sector; Received Minister of Health and Society Award for increased exports of pharmaceutical products; Received presidential award on Science Day (Order of Iron Tower Industry); Received presidential award for 2 million USD export; Received presidential award on Labor Day Received (Order of Iron Tower Industry); Received the first genetic engineering patent in Korea
1986: Received Minister of Health and Society Award for export contributions; Designated as KGMP-eligible company; URSA - Designated as official provider for Asian Games and the ‘88 Seoul Olympics
1985: Yoon Young-hwan appointed as chairman, Lee Cheol-bae appointed as president
1984: Received approval to establish central research institute; Completed construction of Daewoong Lilly Plant
1983: Employees began to move-in into new employee apartments; Received Korea Management Awards (education); Established central research institute
1982: Established Daewoong Lilly Pharmaceutical; Received Order of Gold Tower Industry on Tax Day
1981: Moved HQ to Seocho-dong
1980: Sales exceeded 10 billion KRW

Growth to Korea’s top pharmaceutical company

1979 ~ 1970

1979: Completed production facilities for injection-type antibiotics, opened hospital department
1978: Changed company name to Daewoong Pharmaceutical
1977: Excellence award at the Corporate Public Announcement Conference
1976: Raw materials and technology partnership with Gitse Siraimasu Pharmaceutical of Japan; Began publication of Daewoong Newsletter
1974: Establish Subsidiary Pharmaceutical Research Center
1973: IPO (4th in pharmaceutical industry)
1972: Completed Seongnam plant and moved HQ to Seoul

Daewoong’s dream to build a national company that can contribute to society

1969 ~ 1945

1966: Yoon Young-hwan appointed as CEO
1961: Changed company name to Daehan Vitamin Industries (CEO Park Moon-soo, capital 10 million KRW); Launched URSA
1959: Moved to new building in Choeup-dong, Busan
1954: Approval for pharmaceutical product manufacturing (Ministry of Health and Society No. 43)
1949: Received Vice President Award at the outstanding domestic product exhibit for the first time in Korea
1945: Founded Joseon Ganyu Pharmaceutical Company